Showing 15 posts of 98 posts found.


Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review

April 16, 2019
Manufacturing and Production, Sales and Marketing EMA, Genzyme, Lemtrada, multiple sclerosis, pharma

The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues …


Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership

April 8, 2019
Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease

Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …


PureTech’s Vedanta Biosciences appoints former Genzyme VP chief scientific officer

March 16, 2016
Medical Communications, Research and Development Bruce Roberts, Genzyme, Vedanta Biosciences

Vedanta Biosciences, a company developing therapies designed to modulate the human microbiome, has appointed former Genzyme group vice president, Bruce …


Cancer drugs prices vary up to 388% between high-income countries

December 4, 2015
Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology

The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …


Companies face mixed fortunes in ultra-orphan approvals

November 26, 2015
Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs

UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …


Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015
Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …


Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial

October 7, 2015
Research and Development Genzyme, MS, Sanofi

Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …


Genzyme opts into Alnylam’s Thrombosis program

October 2, 2015
Medical Communications, Research and Development Alnylam, Genzyme, Sanofi, haemophilia

Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in …


Sanofi sales boosted by rare disease and multiple sclerosis drugs

July 30, 2015
Manufacturing and Production, Sales and Marketing Genzyme, Oliver Brandicourt, Sanofi, brandicourt, financial results

Sales at pharma giant Sanofi increased by 5% in the second quarter of 2016 to nearly €10 billion, its latest …

Sanofi image

Sanofi makes gene therapy move

February 13, 2015
Research and Development, Sales and Marketing Genzyme, Sanofi, Voyager Therapeutics, gene therapy, merger

Sanofi has signalled its intent to develop gene therapy treatments for nerve diseases through a $745 million deal with US …

Sanofi image

Sanofi sales lifted by diabetes and rare diseases

February 6, 2015
Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4

Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …

Genzyme image

FDA green lights Lemtrada for MS

November 17, 2014
Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera

The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …

Sanofi image

FDA approves Sanofi’s new rare disease drug

August 20, 2014
Research and Development, Sales and Marketing Elelyso, Gaucher disease, Genzyme, Sanofi, eliglustat

Sanofi’s biologics unit Genzyme has been granted approval for a new drug to treat the rare genetic disorder Gaucher’s disease. …

Sanofi image

Priority review for Gaucher drug

December 12, 2013
Sales and Marketing EMA, FDA, Gaucher, Genzyme, Sanofi

The FDA is to conduct a speedy investigation into Sanofi’s twice-daily oral candidate for Gaucher disease, which means that Cerdelga …

Latest content